NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Nucleophosmin (NPM1) mutations are common in acute myeloid leukemia and are associated with high remission rates and prolonged survival with intensive chemotherapy. NPM1 mutations are rare in myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN), and the clinical o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Montalban-Bravo, Guillermo, Kanagal-Shamanna, Rashmi, Sasaki, Koji, Patel, Keyur, Ganan-Gomez, Irene, Jabbour, Elias, Kadia, Tapan, Ravandi, Farhad, DiNardo, Courtney, Borthakur, Gautham, Takahashi, Koichi, Konopleva, Marina, Komrokji, Rami S., DeZern, Amy, Kuzmanovic, Teodora, Maciejewski, Jaroslaw, Pierce, Sherry, Colla, Simona, Sekeres, Mikkael A., Kantarjian, Hagop, Bueso-Ramos, Carlos, Garcia-Manero, Guillermo
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2019
Assuntos:
Myeloid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6436014/
https://ncbi.nlm.nih.gov/pubmed/30902805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018026989
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares